(Q34307160)

1 August 2017

1 reference

title

Selective immunointervention in autoimmune diseases: lessons from multiple sclerosis (English)

1 reference

1 August 2017

0 references

Adorini L

1

1 reference

1 August 2017

publication date

1 June 2001

1 reference

1 August 2017

published in

Journal of Chemotherapy

1 reference

1 August 2017

volume

13

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

219-234

1 reference

Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Determinant spreading and the dynamics of the autoimmune T-cell repertoire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Peripheral deletion of antigen-reactive T cells in oral tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Double-Blind Pilot Trial of Oral Tolerization with Myelin Antigens in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Tickling the TCR: selective T-cell functions stimulated by altered peptide ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Interleukin 10-mediated immunosuppression by a variant CD4 T cell epitope of Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Altered peptide ligands narrow the repertoire of cellular immune responses by interfering with T-cell priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Microbial epitopes act as altered peptide ligands to prevent experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

The role of Fas and related death receptors in autoimmune and other disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Soluble antigen therapy induces apoptosis of autoreactive T cells preferentially in the target organ rather than in the peripheral lymphoid organs

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

CD28/B7 system of T cell costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

CD40 AND CD154 IN CELL-MEDIATED IMMUNITY

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Absence of co-stimulation and not the intensity of TCR signaling is critical for the induction of T cell unresponsiveness in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Mechanisms of immunotherapeutic intervention by anti-CD40L (CD154) antibody in an animal model of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

CTLA-4: a negative regulator of autoimmune disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Purified protein derivative of Mycobacterium tuberculosis and excretory-secretory antigen(s) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profile of cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Lymphocyte responses and cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Cytokines induce the development of functionally heterogeneous T helper cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

The regulation of immunity to Leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Lymphokine production by human T cells in disease states

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

The expanding universe of T-cell subsets: Th1, Th2 and more.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Late complications of immune deviation therapy in a nonhuman primate

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Limited heterogeneity of T cell receptors from lymphocytes mediating autoimmune encephalomyelitis allows specific immune intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Interferon-gamma confers resistance to experimental allergic encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Impaired IL-12 responses and enhanced development of Th2 cells in Stat4-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Uveitogenicity is associated with a Th1-like lymphokine profile: cytokine-dependent modulation of early and committed effector T cells in experimental autoimmune uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Human tumor necrosis factor-alpha augments experimental allergic encephalomyelitis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Interleukin-10 induces a long-term antigen-specific anergic state in human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: a novel gene therapy approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Contrasting effect of alpha/beta- and gamma-interferons on expression of macrophage Ia antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Exacerbations of multiple sclerosis in patients treated with gamma interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Immunologic therapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Interferon (IFN)-beta treatment enhances CD95 and interleukin 10 expression but reduces interferon-gamma producing T cells in MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Regulation of immune responses by TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Experimental allergic encephalomyelitis: Neutralizing antibody to TGFβ1 enhances the clinical severity of the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

TGF-beta: a balancing act.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Regulation of autoimmune disease physiological and therapeutic

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

MHC-Restricted Depletion of Human Myelin Basic Protein-Reactive T Cells by T Cell Vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Vaccination against experimental allergic encephalomyelitis with T cell receptor peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

T cell receptor peptide therapy triggers autoregulation of experimental encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Epitope specificity and V gene expression of cerebrospinal fluid T cells specific for intact versus cryptic epitopes of myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

TCR usage in human and experimental demyelinating disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Adhesion molecules in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Chemokines and leukocyte traffic

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Definition, function and pathophysiological significance of chemokine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Chemokines and chemokine receptors in inflammation of the nervous system: manifold roles and exquisite regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Chemokine receptor antagonism as a new therapy for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Treatment of Uveitis by Oral Administration of Retinal Antigens: Results of a Phase I/II Randomized Masked Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Interferon-β treatment in multiple sclerosis patients decreases the number of circulating T cells producing interferon-γ and interleukin-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

Vaccination against autoimmune encephalomyelitis with T-lymphocite line cells reactive against myelin basic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1179%2FJOC.2001.13.3.219

10.1179/JOC.2001.13.3.219

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference